Angelo A. Manfredi

TL;DR: Some recent advances in the effector and regulatory action of neutrophils and in the outcome of their interaction with circulating platelets are discussed in light of potential clinical and therapeutic implications in the near future.

TL;DR: It is suggested that specific recognition of mycobacterial Ag by γ δ T lymphocytes in co‐infected individuals may modulate viral replication through the complex array of soluble factors released.

TL;DR: The overall performance of the automated method exceeded that of expert raters, with the worst misdiagnosis when discriminating between neuromyelitis optica spectrum disorders and vasculitis or migraine.

TL;DR: Recent evidence is discussed that implicates the prototypic damage-associated molecular pattern/alarmin, the high mobility group box 1 (HMGB1) protein in systemic vasculitis and in the vascular inflammation associated with systemic sclerosis, a player in the pathogenesis of rheumatic diseases and an attractive target for molecular interventions.

TL;DR: The level of evidence of available published interventional studies is evaluated, with a focus on randomised controlled trials and the efficacy of therapies on clinical outcomes, and a large cohort of well-characterized patients hospitalized at a single University Hospital in Milano (Italy), correlating viral clearance with clinical and biochemical features of patients are presented.